Participants experiencing intractable cancer related pain

IRB #24455
A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated with Advanced Cancer

Participants with metastatic colorectal cancer who will be receiving FOLFOX and Bevacizumab

IRB #23857
A double-blind, placebo-controlled, randomized, dose-escalating study to assess the safety and tolerability of ART-123 in combination with FOLFOX and bevacizumab in metastatic colorectal cancer

Participants with advanced cancer and anorexia

IRB #24724
ACTO: A phase II, randomized, placebo-controlled study evaluating olanzapine in the management of cancer cachexia

Participants experiencing cancer therapy-related diarrhea

IRB #23555
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy (OnTARGET)

Participants planning to receive immune checkpoint inhibitor therapy

IRB #24032
SWOG - S2013 - Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

http://www.ohsu.edu/research/rda/so/knight.php
Participants with advanced cancer experiencing anorexia and weight loss

IRB #24786
A phase 2 randomized, double-blind, placebo controlled study to evaluate ponsegrromab in patients with cancer, cachexia, and elevated concentrations of GDF-15, followed by an optional open-label treatment period

http://www.ohsu.edu/research/nda/so/knight.php